AstraZeneca has reported promising results from two late-stage trials of its experimental drug tozorakimab for chronic obstructive pulmonary disease (COPD), which could lead to substantial sales growth for the company.
The drug, currently under priority review by the FDA, demonstrated a reduction in moderate and severe flare-ups among COPD patients, with a 29% to 34% decrease in flare-ups for former smokers compared to a placebo. AstraZeneca has raised its peak annual sales forecast for tozorakimab to over $5 billion, contributing to its broader goal of achieving $80 billion in revenue by 2030.
CEO Pascal Soriot emphasized the drug's potential to serve a large patient population, particularly since existing biologics for COPD are underutilized.
The drug's unique mechanism of action, targeting two pathways of the inflammatory protein IL-33, may explain its efficacy across a wider range of patients, including those with lower eosinophil counts, a group often overlooked by current treatments. Experts, including Dr.
Meilan Han from the University of Michigan, express excitement about the data but call for further analysis to determine the drug's optimal use relative to existing therapies. The ongoing regulatory review in major markets and the drug's potential applications in severe asthma and viral respiratory diseases further underscore its significance in the respiratory treatment landscape.
Additionally, growing environmental concerns related to air quality may increase the prevalence of COPD, highlighting the urgent need for effective treatments like tozorakimab